Efavirenz urolithiasis.
Izzedine
Hassane
H
Valantin
Marc Antoine
MA
Daudon
Michel
M
Mohand
Hocine Ait
HA
Caby
Fabienne
F
Katlama
Christine
C
D000480:Alkynes; D000069446:Atazanavir Sulfate; D048588:Benzoxazines / Q000009:adverse effects*; D003521:Cyclopropanes; D004359:Drug Therapy, Combination; D017320:HIV Protease Inhibitors / Q000009:adverse effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D009842:Oligopeptides / Q000009:adverse effects; D011725:Pyridines / Q000009:adverse effects; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects*; D019438:Ritonavir / Q000009:adverse effects; D052878:Urolithiasis / Q000139:chemically induced*
D000480:Alkynes; D048588:Benzoxazines; D003521:Cyclopropanes; D017320:HIV Protease Inhibitors; D009842:Oligopeptides; D011725:Pyridines; D018894:Reverse Transcriptase Inhibitors; D000069446:Atazanavir Sulfate; C098320:efavirenz; D019438:Ritonavir